Immune checkpoint inhibitors for patients with pre-existing autoimmune diseases.
作者信息
Maeda Osamu
机构信息
Department of Clinical Oncology and Chemotherapy, Nagoya University Hospital, Nagoya, Japan.
出版信息
Nagoya J Med Sci. 2023 Feb;85(1):33-34. doi: 10.18999/nagjms.85.1.33.
Abstract
摘要
相似文献
1
Immune checkpoint inhibitors for patients with pre-existing autoimmune diseases.
Nagoya J Med Sci. 2023 Feb;85(1):33-34. doi: 10.18999/nagjms.85.1.33.
2
[Myasthenia gravis associated with nivolumab].
Rev Neurol. 2020 Jan 16;70(2):72-73. doi: 10.33588/rn.7002.2019153.
3
Combination anti-PD1 and ipilimumab therapy in patients with advanced melanoma and pre-existing autoimmune disorders.
J Immunother Cancer. 2021 May;9(5). doi: 10.1136/jitc-2020-002121.
4
Single or dual immune checkpoint inhibitor as adjuvant therapy in advanced melanoma.
Eur J Cancer. 2021 Apr;147:140-141. doi: 10.1016/j.ejca.2021.01.031. Epub 2021 Mar 1.
5
Durable Metastatic Melanoma Remission Following Pembrolizumab and Radiotherapy: A Case Report of Prophylactic Immunosuppression in a Patient with Myasthenia Gravis and Immune-Mediated Colitis.
Front Immunol. 2021 Dec 8;12:788499. doi: 10.3389/fimmu.2021.788499. eCollection 2021.
6
Severe Exacerbation of Myasthenia Gravis Associated with Checkpoint Inhibitor Immunotherapy.
J Neuromuscul Dis. 2017;4(2):169-173. doi: 10.3233/JND-170219.
7
Acetylcholine receptor binding antibody-associated myasthenia gravis and rhabdomyolysis induced by nivolumab in a patient with melanoma.
Jpn J Clin Oncol. 2016 Jan;46(1):86-8. doi: 10.1093/jjco/hyv158. Epub 2015 Oct 21.
8
Association Between Sex and Immune Checkpoint Inhibitor Outcomes for Patients With Melanoma.
JAMA Netw Open. 2021 Dec 1;4(12):e2136823. doi: 10.1001/jamanetworkopen.2021.36823.
9
Concurrent Vogt-Koyanagi-Harada disease and impressive response to immune checkpoint blockade in metastatic melanoma.
Immunotherapy. 2020 May;12(7):439-444. doi: 10.2217/imt-2019-0206. Epub 2020 Apr 19.
10
A case of Schönlein-Henoch purpura induced by immune checkpoint inhibitor in a patient with metastatic melanoma.
Eur J Cancer. 2020 Nov;139:169-172. doi: 10.1016/j.ejca.2020.08.005. Epub 2020 Sep 29.
本文引用的文献
1
Immunotherapy use outside clinical trial populations: never say never?
Ann Oncol. 2021 Jul;32(7):866-880. doi: 10.1016/j.annonc.2021.03.199. Epub 2021 Mar 24.
2
Use of Immune Checkpoint Inhibitors in the Treatment of Patients With Cancer and Preexisting Autoimmune Disease: A Systematic Review.
Ann Intern Med. 2018 Jan 16;168(2):121-130. doi: 10.7326/M17-2073. Epub 2018 Jan 2.
3
Nivolumab-related myasthenia gravis with myositis and myocarditis in Japan.
Neurology. 2017 Sep 12;89(11):1127-1134. doi: 10.1212/WNL.0000000000004359. Epub 2017 Aug 18.
4
Myasthenia gravis: An emerging toxicity of immune checkpoint inhibitors.
Eur J Cancer. 2017 Sep;82:128-136. doi: 10.1016/j.ejca.2017.05.041. Epub 2017 Jun 27.
5
Nivolumab for the treatment of malignant melanoma in a patient with pre-existing myasthenia gravis.
Nagoya J Med Sci. 2016 Feb;78(1):119-22.
Zotero 插件